First-Line Treatment Intensification in EGFR-Mutated NSCLC: Overall Survival Data and Regimen Selection

Dr. Jonathan Riess introduces the program on first-line treatment strategies in EGFR-mutated NSCLC, joined by Dr. Mary Jo Fidler and Dr. Matthew Gumbleton. He frames the discussion around the paradigm shift from osimertinib monotherapy to two combination strategies demonstrating overall survival (OS) benefit: amivantamab plus lazertinib from MARIPOSA, and osimertinib plus platinum-pemetrexed from FLAURA2, both now NCCN Category 1 preferred frontline options. High-risk subgroups, including patients with TP53 co-mutations and CNS metastases, derive particularly meaningful benefit from frontline combination approaches over single-agent tyrosine kinase inhibitor (TKI) therapy.

Dr. Fidler explains her communication approach with patients receiving a new diagnosis of EGFR-mutated NSCLC: the 18-month OS rates of 82% and 89% with the 2 combination regimens, respectively, represent meaningful improvements over the approximately 18-month median progression-free survival (PFS) historically seen with osimertinib monotherapy. She now recommends frontline combination therapy for all eligible patients with newly diagnosed EGFR-mutated advanced NSCLC, reserving osimertinib monotherapy for patients in whom, through shared decision-making, a de-intensified approach is clearly appropriate. She looks for a reason not to offer combination therapy rather than a reason to add it.

Regarding toxicity-driven regimen selection, Dr. Fidler notes that toxicity with both intensified regimens is largely front-loaded. With amivantamab-lazertinib, dermatologic toxicities predominate but often stabilize by approximately 4 months. With osimertinib plus carboplatin-pemetrexed, hematologic and gastrointestinal toxicities are more prominent during the induction phase with both chemotherapy agents; carboplatin is discontinued after induction but pemetrexed-related toxicities continue during maintenance, noting that not all patients in FLAURA2 completed the planned pemetrexed course.